BioMe Oxford Ltd is developing a pill-sized gut-sampling device that enables targeted, minimally invasive collection of microbiome samples from any part of the intestines. This technology addresses the limitations of existing sampling methods, which are often invasive, costly, and inaccurate, thereby enhancing research and diagnostic capabilities related to gut health.
Funding
$90K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for sampling the gut microbiome are often invasive, costly, and inaccurate, limiting research and diagnostic capabilities related to gut health. Existing techniques lack the ability to target specific locations within the intestines, hindering precise analysis of microbial communities.
Solution
BioMe Oxford Ltd is developing a pill-sized, ingestible device that enables targeted and minimally invasive collection of microbiome samples from any part of the intestines. This technology overcomes the limitations of existing sampling methods by providing a cost-effective and precise way to access specific regions of the gut. The device aims to improve understanding of the links between microbiome signatures and disease status, ultimately enhancing overall quality of life. By offering targeted sampling, the technology allows for more accurate and detailed analysis of the gut microbiome's composition and function.
Target Audience
The primary users are researchers and clinicians seeking improved methods for studying and diagnosing gut health issues.
Features
- Pill-sized, ingestible device for minimally invasive gut microbiome sampling
- Targeted sample collection from specific locations within the intestines
- Cost-effective alternative to traditional sampling methods